Ahmad Tarhini: Important implications for drug development targeting the microbiome
Ahmad Tarhini, Director, Cutaneous Clinical and Translational Research at Moffitt Cancer Center and Research Institute, shared on LinkedIn:
“Our latest published article | The melanoma tumor microbiome and TME immunogenicity, response and resistance to immune checkpoint inhibitors | Important implications for drug development targeting the microbiome |
Proud of this collaboration with Daniel Spakowicz, Aik Choon Tan, Caroline Dravillas, Sam Coleman.”
Authors: Caroline E. Dravillas, Samuel S. Coleman, Rebecca Hoyd, Griffin Caryotakis, Louis Denko, Carlos H.F. Chan, Michelle L. Churchman, Nicholas Denko, Rebecca D. Dodd, Islam Eljilany, Sheetal Hardikar, Marium Husain, Alexandra P. Ikeguchi, Ning Jin, Qin Ma, Martin D. McCarter, Afaf E.G. Osman, Lary A. Robinson, Eric A. Singer, Gabriel Tinoco, Cornelia M. Ulrich, Yousef Zakharia, Daniel Spakowicz, Ahmad A. Tarhini, Aik Choon Tan.
Source: Ahmad Tarhini/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023